PGNY Progyny, Inc.
USHealthcareAs of 2026-07-10 16:00
Why PGNY matters now
Progyny, Inc. (PGNY) is a US stock in Healthcare. The latest InvestLog snapshot shows $30.65 with -1.35% on the session and $2.40B in market capitalization; recent performance reads 1-month +6.02% and YTD +1.56%.
The latest financial table shown here is Q1 2026, with revenue of $328.5M, net income of $24.2M, and EPS of $0.29. Investors can compare that operating picture with valuation signals such as P/E 24.02 and FCF yield 9.0%.
The latest indexable market news headline is "Why Progyny (PGNY) Might be Well Poised for a Surge" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $30.00; recent insider activity includes Swartz Allison filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
24.02
PEG
3.12
P/B
4.80
P/S
1.58
EV/EBITDA
17.44
DCF Value
$22.31
FCF Yield
9.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
24.1%
Operating Margin
7.5%
Net Margin
5.2%
ROE
13.3%
ROA
9.7%
ROIC
13.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $328.5M | $24.2M | $0.29 |
| Q4 2025 | $318.4M | $12.5M | $0.14 |
| FY 2025 | $1.29B | $58.5M | $0.65 |
| Q3 2025 | $313.3M | $13.9M | $0.15 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$30.33
Target (Median)
$30.00
Target Range
$27.00 - $35.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Country
US
Exchange
—
Beta
1.04
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.